Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Last trade$91.25
Day change-$0.33 (-0.36%)
Day range$89.20 – $95.88
Volume152,578
Market cap$5.98B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.98B
Price / earnings
—
Price / book
-110.33×
Price / sales
8.91×
EV / sales
9.64×
EV / EBITDA
-7.44×
Profitability
Earnings per share
-$13.85
Return on assets
-88.04%
Return on equity
1,668.1%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-13.5×
Current ratio
2.07×
Quick ratio
1.98×
Cash ratio
0.86×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$273.85M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MIRM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$185.72M
$176.24M
$159.88M
$148.93M
$133.01M
$127.79M
$111.59M
$99.41M
Cost of revenue
$35.17M
$30.35M
$28.81M
$28.26M
$25.54M
$23.42M
$23.02M
$22.78M
Gross profit
$150.55M
$145.9M
$131.08M
$120.67M
$107.47M
$104.36M
$88.57M
$76.63M
Selling, general and administrative
$88.86M
$81.47M
$96.33M
$74.13M
$61.91M
$63.29M
$57.71M
$56.83M
Research and development
$121.43M
$106.96M
$824.21M
$51.11M
$42.96M
$46.07M
$46.04M
$44.03M
Total operating expenses
$210.3M
$188.43M
$920.54M
$125.24M
$104.87M
$109.35M
$103.75M
$100.86M
Operating income
-$59.75M
-$42.54M
-$789.47M
-$4.57M
$2.6M
-$4.99M
-$15.18M
-$24.22M
Interest expense
-$1.61M
-$2.62M
-$3.62M
-$3.6M
-$3.61M
-$3.59M
-$3.6M
-$3.58M
Income before taxes
-$40.23M
-$65.54M
-$789.68M
-$4.96M
$2.64M
-$5.46M
-$13.65M
-$24.37M
Income taxes
$538K
$1.69M
$475K
$767K
-$262K
$402K
$1.03M
-$576K
Net income
-$40.77M
-$67.23M
-$790.16M
-$5.73M
$2.91M
-$5.86M
-$14.68M
-$23.79M
Net income attributable to common shareholders
-$40.77M
-$67.23M
-$790.16M
-$5.73M
$2.91M
-$5.86M
-$14.68M
-$23.79M
EBITDA
-$52.86M
-$35.6M
-$782.59M
$1.51M
$8.67M
$1.07M
-$9.13M
-$18.17M
Basic earnings per share
-$0.62
-$1.06
-$13.43
-$0.11
$0.06
-$0.12
-$0.30
-$0.49
Diluted earnings per share
-$0.62
-$1.06
-$13.43
-$0.13
$0.05
-$0.12
-$0.30
-$0.49
Recent news
Company coverage with links to the original publishers.
Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.
Mirum Pharmaceuticals (MIRM) is expected to report Q3 2026 earnings with a consensus loss of $0.53 per share but revenues up 32.7% year-over-year to $176.46 million. With a positive Earnings ESP of +56.93% and Zacks Rank #3, the company is positioned to likely beat consensus EPS estimates. The stock has beaten estimates twice in the last four quarters.
Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.
Mirum Pharmaceuticals announced that brelovitug met the primary endpoint in the phase III AZURE-1 study for chronic hepatitis delta virus (HDV) treatment. 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks achieved virologic response and ALT normalization compared to 0% in the delayed-treatment arm. The drug was well-tolerated with no new safety concerns. Phase III AZURE-4 data are expected in Q4 2026, with a potential BLA submission planned for H1 2027 and commercial launch expected in Q4 2027.
Arcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its ZORYVE (roflumilast) franchise for treating inflammatory skin diseases and evaluates pipeline expansion through strategic acquisitions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.